Copyright
©The Author(s) 2016.
World J Transplant. Jun 24, 2016; 6(2): 380-388
Published online Jun 24, 2016. doi: 10.5500/wjt.v6.i2.380
Published online Jun 24, 2016. doi: 10.5500/wjt.v6.i2.380
Figure 2 Influence of chemotherapy on overall survival.
A: Overall survival (OS) based on hematologic response. The median OS for the 11 non-responders/non-evaluable patients was 1.2 years. The median OS for the 5 patients achieved VGPR or PR was 5.4 years. The median OS for the 7 patients achieving CR was 10.8 years; B: OS based on whether or not patient received AHSCT. The median OS for the 10 patients not undergoing AHSCT was 2.4 years; the median OS For the 13 patients undergoing AHSCT was 6.3 years. VGPR: Very good partial response; CR: Complete hematologic response; AHSCT: Autologous hematopoietic stem cell transplantation.
- Citation: Grogan M, Gertz M, McCurdy A, Roeker L, Kyle R, Kushwaha S, Daly R, Dearani J, Rodeheffer R, Frantz R, Lacy M, Hayman S, McGregor C, Edwards B, Dispenzieri A. Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience. World J Transplant 2016; 6(2): 380-388
- URL: https://www.wjgnet.com/2220-3230/full/v6/i2/380.htm
- DOI: https://dx.doi.org/10.5500/wjt.v6.i2.380